Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation

Blood

Volumn 119, Issue 24, 2012, Pages 5750-5757

  Vanderford, Thomas H ^a,b   Slichter, Chloe ^a   Rogers, Kenneth A ^a   Lawson, Benton O ^a   Obaede, Rend ^a,c   Else, James ^a   Villinger, Francois ^a   Bosinger, Steven E ^a,b   Silvestri, Guido ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2 INTERFERON;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CERCOCEBUS; DISEASE COURSE; DRUG ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE ACTIVATION; IMMUNOLOGICAL PARAMETERS; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECTUM BIOPSY; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; TREATMENT DURATION; UPREGULATION; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 84862491847     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-411496     Document Type: Article

References (47)

1. Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol. 2005;79(7):4043-4054. (Pubitemid 40388344)
2. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18(3):441-452. (Pubitemid 36351522)
3. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science. 2012;335(6073):1188-1193.
4. Bosinger SE, Li Q, Gordon SN, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest. 2009;119(12):3556-3572.
5. Paiardini M, Cervasi B, Reyes-Aviles E, et al. Low levels of SIV infection in sooty mangabey central memory CD T cells are associated with limited CCR5 expression. Nat Med. 2011;17(7):830-836.
6. Butler SL, Valdez H, Westby M, et al. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(3):297-303.
7. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood. 2011;117(21):5582-5590.
8. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870. (Pubitemid 29159331)
9. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29(4):346-355. (Pubitemid 34288887)
10. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92.
11. Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296(12):1498-1506.
12. Gordon SN, Klatt NR, Bosinger SE, et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol. 2007;179(5):3026-3034.
13. Jacquelin B, Mayau V, Targat B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119(12):3544-3555.
14. Pandrea IV, Gautam R, Ribeiro RM, et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol. 2007;179(5):3035-3046.
15. Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol. 1995;155(8):3946-3954.
16. Eberly MD, Kader M, Hassan W, et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J Immunol. 2009;182(3):1439-1448.
17. Onlamoon N, Rogers K, Mayne AE, et al. Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology. 2008;124(2):277-293. (Pubitemid 351692908)
18. Betts MR, Nason MC, West SM, et al. HIV non-progressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781-4789. (Pubitemid 43882629)
19. Dunham R, Pagliardini P, Gordon S, et al. The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood. 2006;108(1):209-217. (Pubitemid 43990631)
20. Engram JC, Dunham RM, Makedonas G, et al. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol. 2009;183(1):706-717.
21. Taaffe JE, Bosinger SE, Del Prete GQ, et al. CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques. J Med Primatol. 2012;41(1):24-42.
22. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
23. Berglund AC, Sjolund E, Ostlund G, Sonnhammer EL. InParanoid 6: eukaryotic ortholog clusters with inparalogs. Nucleic Acids Res.2008;36(Database issue):D263-D266. (Pubitemid 351149733)
24. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008;14(10):1077-1087.
25. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15(8):955-959.
26. Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918-1921.
27. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654-657.
28. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451(7177):425-430. (Pubitemid 351158893)
29. Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481-485.
30. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646-650.
31. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427(6977):848-853. (Pubitemid 38297747)
32. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444-2451. (Pubitemid 44903748)
33. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23(3):585-591. (Pubitemid 26304511)
34. Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV coinfected patients. Aids. 2007;21(14):1855-1865. (Pubitemid 47329762)
35. Arizcorreta A, Marquez M, Fernandez-Gutierrez C, et al. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol. 2006;146(2):270-277. (Pubitemid 44581342)
36. Landau A, Batisse D, Duong Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. Aids. 2000;14(7):839-844. (Pubitemid 30303461)
37. Pesce A, Taillan B, Rosenthal E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet. 1993;341(8860):1597. (Pubitemid 23170489)
38. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection. Lancet. 1993;341(8850):958-959. (Pubitemid 23109136)
39. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208(10):2005-2016.
40. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637-650. (Pubitemid 41248415)
41. Pinto AK, Daffis S, Brien JD, et al. A temporal role of type I interferon signaling in CD8 T cell maturation during acute West Nile Virus infection. PLoS Pathog. 2011;7(12):e1002407.
42. Bochtler P, Kroger A, Schirmbeck R, Reimann J. Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells. J Immunol. 2008;181(3):1633-1643.
43. Terawaki S, Chikuma S, Shibayama S, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186(5):2772-2779.
44. Herbeuval JP, Grivel JC, Boasso A, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005;106(10):3524-3531. (Pubitemid 41609189)
45. Herbeuval JP, Hardy AW, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2005;102(39):13974-13979. (Pubitemid 41377688)
46. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919-923. (Pubitemid 29372419)
47. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol. 2001;167(4):1862-1866. (Pubitemid 32747488)